Skip to main content
Signal8

Vaxcyte, Inc. (PCVX)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vaxcyte, Inc. logo

Vaxcyte, Inc.

NASDAQ:PCVXHealthcare
Pre-0.89%$63.32
Close$63.89+3.18%AH$64.05-1.14%since
Mkt Cap$10.11B
Float130.56M
O/S158.3M
PM VOL252 sh
$ Vol≈$16K
RVOL0.36×
Inst Own-
SI11.2%
Dilution
Vaxcyte, Inc. logoNASDAQ:PCVXPre$63.32-0.89%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202661.9265.3061.1463.891,841,189
Nov 5, 202665.8865.8861.8461.921,833,845
Nov 4, 202662.8765.7160.0465.682,257,760
Nov 3, 202661.3861.8960.3260.812,176,572
Nov 2, 202661.8862.8760.1560.621,320,466
Oct 30, 202662.5963.2761.0262.031,714,583
Oct 29, 202661.8863.1461.6462.612,013,891
Oct 28, 202659.9263.9459.5861.462,212,723
Oct 27, 202659.9261.3059.4360.672,587,481
Oct 26, 202660.6861.5059.1959.971,469,429
Oct 23, 202662.3562.7760.2760.432,062,419
Oct 22, 202662.9664.5861.5662.852,771,328
Oct 21, 202666.0267.4763.0963.233,272,337
Oct 20, 202663.8067.0163.6866.231,956,844
Oct 19, 202664.1466.0263.3863.682,549,162
Oct 16, 202665.1365.3462.5463.623,250,015
Oct 15, 202667.7268.3365.0065.272,448,480
Oct 14, 202667.0769.2066.0067.551,525,370
Oct 13, 202670.5871.0966.6366.802,645,053
Oct 12, 202671.0872.8968.9770.652,427,716
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$123.50+93.3%
Low $122High $125
Ratings Distribution
BUY
11
HOLD
0
SELL
0
TOTAL11
Insider Trades
InsiderTypeShares
Cowan Elvia profile photoCowan ElviaSale586
Cowan Elvia profile photoCowan ElviaOption Exercise3.0K
Wassil Jim profile photoWassil JimSale1.9K
Cowan Elvia profile photoCowan ElviaOption Exercise3.0K
Wassil Jim profile photoWassil JimOption Exercise2.3K
Wassil Jim profile photoWassil JimOption Exercise2.3K
Shareholders
-
Institutionalⓘ
(352)
0.6%
Insiderⓘ
(15)
15.1%
5%+ Owners
(2)
-
Unattributed (incl. retail)ⓘ
Insider0.6%
5%+ Beneficial15.1%
Sources: 13F, Form 4, 13D/13GO/S: 158.3M · as of 2 Nov 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines.

Its primary objective is to either prevent or manage bacterial infectious diseases.

The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Key Metrics
Market Cap$10.11B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

13F filers report 167.79M shares, more than the 158.30M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJun 12, 2020
Shares Outstanding158.30M
Authorized Shares
Float130.56M
52-Week Range
$29.08$65.00
$63.89(97th percentile)
Volume
Average Daily Volume2.22M
1.84M today vs 2.22M avg(-17%)

30d Avg

2.22M

60d Avg

2.80M

90d Avg

2.19M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...